Last updated 2026-07-27
TL;DR
Tirzepatide has a half life of approximately 5 days, according to the FDA label for Mounjaro and Zepbound. That's why it's dosed once weekly. Full clearance from the body takes about 5 half lives, or roughly 25 to 35 days, which matters for missed doses, surgery planning, and how long side effects or appetite suppression can linger after stopping.
What is tirzepatide's half life, exactly?
Tirzepatide's terminal half life is about 5 days. That figure comes straight from the FDA-approved prescribing information for both Mounjaro (tirzepatide, approved for type 2 diabetes) and Zepbound (tirzepatide, approved for chronic weight management) [1][2]. Half life is the time it takes for the concentration of a drug in your blood to drop by half. A 5-day half life is unusually long for an injectable peptide. For comparison, regular human insulin has a half life measured in minutes. Tirzepatide's long half life is engineered on purpose: the molecule is attached to a fatty acid chain that binds to albumin in the blood, which slows how fast the kidneys and enzymes can clear it [1]. That's the same basic trick used in semaglutide (half life about 7 days) and liraglutide (half life about 13 hours, much shorter, which is why it's dosed daily). A 5-day half life is also why tirzepatide is dosed once a week instead of once a day. The drug builds up gradually over several doses and then holds a fairly steady level in the blood, rather than spiking and crashing like a short-acting medication would.
How long does it take tirzepatide to reach steady state?
Steady state is reached after roughly 4 weeks of consistent once-weekly dosing. That's the standard rule of thumb for any drug: it takes about 4 to 5 half lives to reach a stable plateau concentration, and 5 half lives at 5 days each lands you at 25 days, close to a month. This is part of why tirzepatide dose titration is spread out over 4-week blocks. The FDA label for Zepbound schedules the starting dose (2.5 mg weekly) for the first 4 weeks, then increases in 2.5 mg increments every 4 weeks up to the target maintenance dose [2]. Each 4-week block gives the drug time to reach a new steady state before the next increase, which is also why side effects (mostly gastrointestinal) tend to cluster right after a dose increase and then settle down. If you're mapping out your own titration schedule, the Tirz Rx dosage guide walks through the standard escalation steps, and the Tirz Rx dosage calculator can help you sanity-check volumes at each step.
How long does tirzepatide stay in your system after the last dose?
As a general pharmacology rule, a drug is considered mostly cleared from the body after about 5 half lives. With tirzepatide's 5-day half life, that puts full clearance at roughly 25 to 35 days after the last dose, essentially about a month, sometimes closer to five weeks for people with slower clearance. This is an approximation, not a hard cutoff. Trace amounts can persist a bit longer, and clearance can be slightly slower in people with reduced kidney function, since renal elimination is one of the pathways involved. The FDA label notes tirzepatide has been studied in patients with renal impairment without dose adjustment being required for most stages, but says less about the tail end of elimination in that population [1]. Practically, this washout period is why appetite suppression and GI side effects don't vanish the day after your last shot. Most people report the appetite-dulling effect tapering off gradually over 3 to 6 weeks after stopping, which lines up with the drug's expected clearance curve. It's also why relapse of appetite and weight regain after discontinuation tends to show up on a similar timeline, something documented in the SURMOUNT-4 trial, where participants who switched from tirzepatide to placebo after 36 weeks regained a significant portion of lost weight over the following 52 weeks [3].
Why does tirzepatide's half life matter for dosing frequency?
The 5-day half life is the direct reason tirzepatide is a once-weekly injection instead of a daily one. A shorter-acting compound would need daily or twice-daily dosing to keep blood levels in a useful range, which is exactly the burden GLP-1/GIP drug design has tried to engineer away from. Because the drug clears slowly, missing a dose by a day or two rarely causes a dramatic drop in effect. The FDA label for Zepbound specifically addresses missed doses: if a dose is missed and it's been less than 4 days (96 hours), take it as soon as possible; if more than 4 days have passed, skip the missed dose and resume the regular weekly schedule on the next scheduled day [2]. That 4-day buffer only makes sense because of how slowly the drug decays in the blood. This flexibility is a real practical advantage over drugs with short half lives, where a missed dose can cause more noticeable symptom rebound. It doesn't mean timing is irrelevant, though. Consistent weekly spacing keeps blood levels more stable and titration on schedule, which is part of why sticking to a fixed injection day matters even with the built-in buffer. If you're building a routine, Tirz Rx how to inject and Tirz Rx injection sites cover the practical side of keeping dosing consistent.
Does the half life differ between Mounjaro, Zepbound, and compounded tirzepatide?
No. The half life is a property of the tirzepatide molecule itself, not the brand name on the vial. Mounjaro (FDA-approved for type 2 diabetes) and Zepbound (FDA-approved for chronic weight management) both contain tirzepatide and share the same pharmacokinetic profile, including the roughly 5-day half life described in both drugs' FDA labeling [1][2]. Compounded tirzepatide, made by a compounding pharmacy rather than the branded manufacturer, is supposed to contain the same active peptide, and if it does, the half life in your body would be expected to behave the same way. The catch is that compounded products aren't FDA-approved, meaning they haven't gone through the agency's premarket review for safety, effectiveness, and manufacturing quality that Mounjaro and Zepbound have. The FDA has published guidance and warnings specifically about compounded semaglutide and tirzepatide products, including concerns about dosing accuracy, sterility, and the use of unapproved salt forms in some products [4]. This matters more for potency and purity than for half life itself. But it's worth being clear-eyed about: a compounded product with less active drug than labeled, or degraded peptide, might behave differently in your body than the pharmacokinetics established in FDA trials, simply because you're not getting the same actual dose. Working with a provider-reviewed source and a pharmacy that does its own quality testing is one way to reduce that uncertainty, which is the model Tirz Rx points patients toward rather than sourcing compounded product itself.
How does tirzepatide's half life compare to other GLP-1 drugs?
| Drug | Active ingredient | Half life | Typical dosing frequency | |
|---|---|---|---|---|
| Zepbound / Mounjaro | Tirzepatide | ~5 days [1][2] | Once weekly | |
| Wegovy / Ozempic | Semaglutide | ~7 days [5] | Once weekly | |
| Saxenda | Liraglutide | ~13 hours [6] | Once daily | |
| Trulicity | Dulaglutide | ~4.7 days [7] | Once weekly | Semaglutide (Wegovy, Ozempic) actually has a slightly longer half life than tirzepatide, about 7 days versus tirzepatide's 5 days, per each drug's respective FDA label [5][1]. That doesn't mean semaglutide is more effective; it's a different molecule targeting GLP-1 receptors alone, while tirzepatide is a dual agonist acting on both GLP-1 and GIP receptors, which is part of why head-to-head data (like the SURMOUNT-5 trial) has shown greater average weight loss with tirzepatide than with semaglutide [8]. Liraglutide (Saxenda) sits at the opposite end, with a half life of roughly 13 hours, which is why it requires a daily injection rather than weekly. Dulaglutide (Trulicity) is close to tirzepatide, at around 4.7 days [7], which also supports once-weekly dosing. The takeaway: a long half life is common across most of the newer weight-loss injectables, and it's specifically what allows the once-weekly schedule that's become standard for this drug class. |
How does half life affect nausea, GI side effects, and dose titration timing?
Because tirzepatide builds up slowly and clears slowly, GI side effects (nausea, vomiting, diarrhea, constipation) tend to track dose changes rather than individual injections. In the SURMOUNT-1 trial, nausea was reported in about 24 to 33% of participants across the tirzepatide dose groups (versus about 10% on placebo), and these effects were most common during the titration phase, then tended to decrease over time [9]. The 4-week gap between dose increases exists partly because of the half life: it gives the body roughly 4 to 5 half lives to adjust to a new blood level of the drug before stepping up again. If a person moves too fast between doses (which happens with unsupervised compounded protocols more than with FDA-monitored branded regimens), GI side effects tend to be worse, because blood levels are still rising when the next increase hits. This is one of the practical arguments for sticking to the labeled titration schedule rather than trying to speed things up. The body genuinely needs the time the half life dictates to adapt. For a full breakdown of the titration schedule and reconstitution steps for compounded vials, see how to reconstitute Tirz Rx.
What does the half life mean for stopping tirzepatide before surgery or a procedure?
Anesthesiologists have raised concerns about GLP-1/GIP drugs and delayed gastric emptying, which increases aspiration risk under sedation. The American Society of Anesthesiologists issued guidance in 2023 recommending holding GLP-1 receptor agonists (a category that includes tirzepatide) before elective procedures requiring sedation or general anesthesia, generally suggesting holding the day of surgery for patients on daily dosing, and holding for a full week for patients on weekly dosing, aligned with the dosing interval rather than the full clearance time [10]. Some surgical and gastroenterology groups have suggested longer holds, given that full clearance takes closer to a month based on 5 half-lives. There isn't full consensus across specialties on exactly how long is enough, and practice varies by institution. If you have a procedure scheduled, this is a conversation to have directly with your surgeon or anesthesiologist, factoring in your specific dose, how recently you titrated, and the type of procedure. Don't assume a single skipped dose is automatically sufficient just because the half life sounds short in absolute terms; 5 days per half life adds up quickly across a clearance window.
Does a longer half life mean tirzepatide is safer or more dangerous?
Neither, really. Half life describes how long the drug's effects and presence in the body last; it doesn't by itself determine risk. What matters more for safety is the drug's known side effect and contraindication profile, which is well documented from FDA trials. Tirzepatide carries a boxed warning for thyroid C-cell tumors, based on findings in rodent studies (not confirmed in humans, but the mechanism concern led FDA to require the warning). It's contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) and in people with Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [1][2]. Beyond that boxed warning, the known risks and signals from the SURPASS and SURMOUNT trial programs include: gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) as the most common adverse events; a signal for acute pancreatitis, reported in a small percentage of trial participants; gallbladder-related events, including cholelithiasis (gallstones), likely tied to rapid weight loss rather than a direct drug effect; and hypoglycemia risk when combined with insulin or sulfonylureas [1][2][9]. A longer half life doesn't make any of these risks worse or better; it just means if a side effect does show up, it may take a bit longer to fully resolve after stopping the drug, in line with the clearance timeline discussed above.
What do the SURPASS and SURMOUNT trials show about tirzepatide's real-world effects?
Tirzepatide's FDA approvals rest on two major trial programs. SURPASS (for type 2 diabetes, leading to Mounjaro's approval) included multiple trials comparing tirzepatide to placebo, insulin, and other diabetes drugs, generally showing A1C reductions in the range of 1.8 to 2.4 percentage points depending on dose and comparator [1]. SURMOUNT (for weight management, leading to Zepbound's approval) is the program most relevant to weight-loss use. SURMOUNT-1 (NCT04184622), the trial in adults with obesity or overweight without diabetes that anchored the Zepbound approval, found average weight loss of about 15% at the 5 mg dose, 19.5% at 10 mg, and 20.9% at 15 mg over 72 weeks, compared to about 3.1% with placebo [9]. SURMOUNT-4 (NCT04660643) specifically studied what happens after stopping: participants who switched from tirzepatide to placebo after an initial 36-week run-in regained a substantial share of the weight they'd lost, while those who stayed on tirzepatide continued losing weight through week 88 [3]. SURMOUNT-5 (NCT05822830), a head-to-head trial against semaglutide, found tirzepatide produced significantly greater average weight loss [8]. These numbers give real context for what the half life and dosing schedule are actually working toward: sustained, weekly-level drug exposure that supports ongoing appetite and glycemic effects, not a one-time intervention.
How long after stopping tirzepatide will side effects and appetite suppression last?
Based on the roughly 5-day half life and standard pharmacokinetic reasoning, most people can expect drug effects, both therapeutic and side effects, to taper off over about 3 to 6 weeks after the last dose, with the drug largely cleared from the body by around 5 weeks. GI side effects like nausea typically fade faster than appetite changes, often within 1 to 2 weeks, since they tend to correlate with peak blood concentration right after a dose rather than the long tail of clearance. Appetite suppression and satiety effects, on the other hand, seem to track more closely with the full elimination curve, which is consistent with the weight regain pattern seen in SURMOUNT-4 over the weeks and months following discontinuation [3]. If you're planning a break or a full stop, thinking through the taper and the cycle length in advance is worth it. The Tirz Rx cycle length guide covers what a planned pause or stop actually looks like week by week, and how that maps onto the drug's clearance timeline.
Frequently asked questions
What is the half life of tirzepatide?
Tirzepatide's terminal half life is approximately 5 days, according to FDA prescribing information for both Mounjaro and Zepbound. This long half life, achieved through an albumin-binding fatty acid attachment, is what allows the drug to be dosed once weekly instead of daily.
How long does tirzepatide stay in your system?
Using the standard rule of 5 half lives for near-complete clearance, tirzepatide stays detectable in the body for roughly 25 to 35 days after the last dose, about a month. Trace amounts and lingering effects on appetite can sometimes extend a bit beyond that window.
How long does it take tirzepatide to reach steady state in the blood?
About 4 weeks of consistent once-weekly dosing. This 4-to-5-half-life window is also why the FDA-labeled titration schedule for Zepbound increases the dose in steps every 4 weeks, giving blood levels time to stabilize before the next increase.
What happens if I miss a dose of tirzepatide?
Per the Zepbound FDA label, if less than 4 days (96 hours) have passed since the missed dose, take it as soon as possible. If more than 4 days have passed, skip that dose and resume your regular weekly schedule on the next scheduled injection day.
Does tirzepatide's half life differ between Mounjaro and Zepbound?
No. Both are built on the tirzepatide molecule and share the same roughly 5-day half life documented in their respective FDA labels. The difference between the two brands is the approved indication (type 2 diabetes for Mounjaro, chronic weight management for Zepbound), not the drug's pharmacokinetics.
Is tirzepatide's half life longer or shorter than semaglutide's?
Semaglutide (Wegovy, Ozempic) has a slightly longer half life, about 7 days, compared to tirzepatide's approximately 5 days. Both support once-weekly dosing regardless, and the difference in half life doesn't directly predict which drug produces more weight loss; that comes down to differences in receptor targets and trial data.
How long before surgery should I stop tirzepatide?
The American Society of Anesthesiologists' 2023 guidance suggests holding weekly GLP-1/GIP drugs like tirzepatide for a full week before procedures requiring sedation, due to delayed gastric emptying and aspiration risk. Some specialists recommend longer holds given the drug's full clearance takes closer to a month. Always confirm timing with your own surgical team.
Why is tirzepatide only dosed once a week?
Because its roughly 5-day half life means blood levels stay elevated long enough that daily dosing isn't necessary. The drug accumulates gradually over the first several weeks and then holds a fairly steady level between weekly injections, which is the basic pharmacokinetic reason behind the once-weekly schedule used in both the SURPASS and SURMOUNT trials.
Does compounded tirzepatide have the same half life as Mounjaro or Zepbound?
If the compounded product genuinely contains pure, correctly dosed tirzepatide, the half life should behave the same way in the body, since half life is a property of the molecule. The concern with compounded products is inconsistent potency or purity, not a different half life, and compounded tirzepatide isn't FDA-approved.
How long does appetite suppression last after stopping tirzepatide?
Most people report appetite effects tapering gradually over 3 to 6 weeks after the last dose, roughly matching the drug's expected clearance timeline. The SURMOUNT-4 trial documented meaningful weight regain in the months following a switch from tirzepatide to placebo, consistent with the drug's effects fading as it clears.
Can kidney or liver problems change how long tirzepatide stays in your system?
Reduced kidney function could plausibly slow clearance somewhat, since the kidneys are one elimination pathway, though FDA labeling doesn't require dose adjustment for most stages of renal impairment. There isn't detailed public data quantifying exactly how much slower clearance is in these populations, so anyone with significant kidney or liver disease should discuss timing specifics with their prescriber.
Does a higher tirzepatide dose take longer to clear than a lower dose?
Half life itself doesn't change much with dose, but higher doses mean more total drug in the system to begin with, so absolute clearance to undetectable levels may take a bit longer at 15 mg than at 2.5 mg, even though both follow the same roughly 5-day half life curve.
Sources
- FDA, Mounjaro (tirzepatide) full prescribing information: Tirzepatide half life of approximately 5 days; boxed warning for thyroid C-cell tumors; contraindication in MEN2/MTC; pharmacokinetic profile
- FDA, Zepbound (tirzepatide) full prescribing information: Zepbound dosing titration schedule, missed dose guidance, half life, boxed warning
- Aronne LJ, et al., JAMA, SURMOUNT-4 trial results: Weight regain after switching from tirzepatide to placebo in SURMOUNT-4 (NCT04660643)
- FDA, Medications containing semaglutide taken for weight loss: FDA guidance and warnings on compounded GLP-1/GIP products, dosing accuracy and quality concerns
- FDA, Wegovy (semaglutide) full prescribing information: Semaglutide half life of approximately 7 days
- FDA, Saxenda (liraglutide) full prescribing information: Liraglutide half life of approximately 13 hours, daily dosing
- FDA, Trulicity (dulaglutide) full prescribing information: Dulaglutide half life of approximately 4.7 days, once-weekly dosing
- Aronne LJ, et al., New England Journal of Medicine, SURMOUNT-5 trial results: Head-to-head SURMOUNT-5 trial (NCT05822830) showing greater weight loss with tirzepatide vs semaglutide
- Jastreboff AM, et al., New England Journal of Medicine, SURMOUNT-1 trial results: SURMOUNT-1 (NCT04184622) weight loss percentages by dose and placebo, GI adverse event rates
- American Society of Anesthesiologists, consensus-based guidance on preoperative GLP-1 receptor agonist use: ASA 2023 guidance recommending holding weekly GLP-1/GIP drugs for one week before procedures with sedation